Celgene IM: Pancreatic Cancer Advisory Board – ASCO 2019
Pancreatic Cancer Advisory Board Meeting
06:00 AM – 08:00 AM, Monday 3 June 2019
Venue TBC, Chicago, IL, USA
Meeting objectives:
• To gain a better understanding of the perception and use of nab-paclitaxel + gemcitabine in metastatic pancreatic cancer across a wide range of countries
• To gain feedback on the current evidence base supporting nab-paclitaxel + gemcitabine in metastatic pancreatic cancer and earlier disease
• To identify country-/region-specific endorsements and/or barriers to the use of nab-paclitaxel + gemcitabine in pancreatic cancer (e.g. treatment guidelines, reimbursement policies)
This meeting is organised by the Celgene International Markets team and is intended for delegates already attending ASCO. As such, no assistance with travel or accommodation is offered.
